Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Hydrocortisone 1% cream	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Hydrocortisone 1% ointment	TA81 - Frequency of application of topical corticosteroids for atopic eczema	Mild potency
Ibrutinib	TA429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation TA491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia TA502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Icosapent Ethyl	TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
Idelalisib (Zydelig)	TA359 - Idelalisib for treating chronic lymphocytic leukaemia
Imatinib (Glivec®)	TA70 - Guidance on the use of imatinib for chronic myeloid leukaemia (partially updated by TA241 and TA251) TA86 - Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours TA326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours TA209 - Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance	Off-label use for melanoma with responsive c-KIT mutation
Imlifidase	TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
Inclisiran (Leqvio®)	TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia	BSSE APC prescribing information regarding Inclisiran
Infliximab	TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab injection (Remicade®, Inflectra®, Remsima®)	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA143 - Adalimumab , etanercept and infliximab for ankylosing spondylitis TA130 - Adalimumab , etanercept and infliximab for the treatment of rheumatoid arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.